Patent · US Active

Use of the cathelicidin LL-37 and derivatives therof for wound healing

US8012933B2 · kind B2 · utility

6Cited by

3References

1Claims

0Family size

Assignee

Lipopeptide AB · SE

Inventors

Mona Ståhle-Bäckdahl · Stockholm, SE
Johan Heilborn · Stockholm, SE
Anders Carlsson · Lund, SE
Conny Bogentoft · Nordstraße, SE

Key dates

Filing date	Sep 12, 2008
Grant date	Sep 6, 2011
Priority date	—
Expiry date	Sep 12, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2500/36
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.